Background
A pharmaceutical development company was working with a compound that showed strong efficacy in vitro but very poor oral bioavailability, limiting its viability as an oral therapeutic.
The Challenge
It was unclear whether any delivery formulation could sufficiently improve the compound’s absorption without altering its therapeutic activity or introducing stability problems.
Technological Uncertainty
It was not known in advance whether a particular formulation approach could overcome the compound’s specific solubility and permeability limitations, or how the formulation would interact with the compound’s stability over shelf life.
Experimental Development
The team systematically tested multiple formulation approaches, including alternative particle engineering and excipient combinations, measuring dissolution rate, simulated absorption, and stability under accelerated conditions for each formulation.
What Failed?
An initial particle-size reduction approach improved dissolution but introduced stability problems during accelerated aging testing, requiring the team to investigate a stabilizing excipient combination that had not been previously used with this compound class.
Technological Advancement
The team developed a formulation combining a specific particle engineering technique with a stabilizing excipient system that met both bioavailability and stability targets, generating new formulation knowledge specific to this compound.
Potentially Relevant SR&ED Activities
- Systematic formulation testing across particle engineering and excipient combinations
- Dissolution and simulated absorption testing across formulations
- Accelerated stability testing to evaluate formulation shelf-life performance
What Would Generally Not Qualify
Manufacturing the finalized formulation at commercial scale using validated, established processes would be routine production and would not itself qualify.
Documentation
Dissolution and stability test data across formulation iterations, technical formulation notes, and comparative analysis of excipient combinations would support this claim.
